Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Spherix Incorporated (formerly Biospherics Incorporated). The company operates two primary business segments: InfoSpherix (information technology and government contracting) and BioSpherix (biotechnology and tagatose licensing). The filing notes a change in accounting presentation for 2002, where indirect costs for the IT Division are now classified as direct contract costs.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Revenue | $3,066,168 | $5,217,727 |
| Net Loss | $(1,110,724) | $(157,077) |
| Loss Per Share (Diluted) | $(0.10) | $(0.01) |
| Cash and Equivalents | $9,069,318 | $5,039,076 |
| Working Capital | $10,177,698 | $7,139,196 |
| Debt (Bank Line of Credit) | $0 | $212,856 |
| Operating Cash Flow | $(1,383,270) | $456,772 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 41% ($2.15 million) compared to Q1 2001. This is primarily attributed to the absence of a one-time $1.3 million revenue recognition in Q1 2001 related to a U.S. Department of Labor settlement with the General Services Administration (GSA).
- Commercial Contract Drop: Revenue from commercial contracts fell by 98% ($719,000) year-over-year, reflecting the sporadic nature of such contracts.
- Increased Operating Loss: The net loss widened significantly to $1.11 million from $157,000. InfoSpherix operating loss increased to $769,000, while BioSpherix operating loss rose to $360,000 due to increased R&D and staffing costs.
- Financing Activity: The company raised approximately $3.85 million in cash through the exercise of warrants by an institutional investor in March 2002, significantly boosting liquidity.
- Expense Shifts: Research and development expenses increased 141% due to a feasibility study for a tagatose pilot plant. Conversely, direct contract costs decreased 34% due to the lack of the GSA settlement costs in the current period.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management reports strong liquidity with over $9 million in cash. The company has a $2 million line of credit with Bank of America, of which $1.39 million was available at quarter-end. The line expires June 30, 2002, and management anticipates renewal.
- Future Revenue: Royalties from the D-tagatose licensing agreement with Arla Foods (formerly MDFI) are anticipated to begin in 2003. A $1 million non-refundable advance is currently recorded as deferred revenue.
- Capital Needs: Management believes current cash flow and reserves are sufficient to meet obligations for the remainder of 2002 without additional financing, though commercial contracts remain sporadic.
- Risks: The company faces risks related to the renewal of its line of credit and the timing of future commercial contracts. Forward-looking statements regarding future performance are subject to standard risks and uncertainties.
Investor Verification Checklist
- Verify the status and renewal terms of the $2 million Bank of America line of credit expiring June 30, 2002.
- Confirm the timeline and probability of royalty revenue commencement from the Arla Foods tagatose agreement in 2003.
- Assess the progress and capital requirements of the BioSpherix pilot plant feasibility study.
- Review the pipeline for new commercial contracts to offset the 98% decline in commercial revenue.
- Monitor the utilization of the $3.85 million raised via warrant exercises to ensure it covers the projected operating cash burn.